Blackstone-backed Cryoport, a provider of cold chain logistics solutions, completed the acquisition of MVE Biological Products, a cryobiological products business, from Chart Industries, a manufacturer of cryogenic equipment, for $320m. “The acquisition is expected to expand Cryoport’s total addressable market, provide our clients’ with expanded end-to-end support across the cell and gene therapy value chain and enhance our innovation pipeline,” Jerrell Shelton, Cryoport CEO.